Merck & Co. Makes a Bold Move: Acquiring Verona Pharma for $10 Billion to Expand Its Biopharmaceutical Portfolio

Merck & Co., Inc. has confirmed its $10 billion acquisition of Verona Pharma, aiming to bolster its biopharmaceutical offerings with Verona's COPD treatment, Ohtuvayre. The deal, e...